Oxford University to Resume Trials of Covid-19 Vaccine
AstraZeneca said on Tuesday, trials of a Covid-19 vaccine will resume after it was paused due to a reported side effect in a patient in the UK.
Trials of a Covid-19 vaccine being developed by AstraZeneca and Oxford University were paused while it investigated whether the reported side effect was connected with the vaccine.
While the vaccine is seen as a strong contender, Oxford University said it would not disclose information about the patient’s illness due to confidentiality reasons, but the New York Times reported that a volunteer in the UK trial had been diagnosed with transverse myelitis, an inflammatory syndrome that affects the spinal cord and can be caused by viral infections.
On the other side, the vaccine is being tested in thousands of people in Britain and the US, and in smaller study groups in Brazil and South America.
Oxford University said in a statement that it was “expected” that “some participants will become unwell” in large trials such as this one.
“Globally some 18,000 individuals have received study vaccines as part of the trial.
“In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.
The government’s chief scientific adviser, Sir Patrick Vallance, echoed this view, telling a Downing Street press conference on Wednesday what had happened in the Oxford trial was not unusual.
He added that similar events should also be expected in some of the other vaccine candidate trials.
Health Secretary Matt Hancock welcomed the news of the trials restarting in a tweet.
Good news for everyone the Oxford vaccine trials are back up and running. This pause shows we will always put safety first. We will back our scientists to deliver an effective vaccine as soon as safely possiblehttps://t.co/RUtTE3sPim
— Matt Hancock (@MattHancock) September 12, 2020
The University of Oxford said: “The ongoing randomised controlled clinical trials of the Oxford coronavirus vaccine ChAdOx1 nCoV-19 will resume across all UK clinical trial sites.
Two other vaccines are in huge, final-stage tests in the United States, one made by Moderna and the other by Pfizer and Germany’s BioNTech.
Despite some figures, such as US President Donald Trump, insisting a vaccine will be ready in a matter of months, Oxford University has said a vaccine might not be ready before 2022.
You might also be interested in: